Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base
Launched by HEIDELBERG UNIVERSITY · Aug 16, 2010
Trial Information
Current as of May 18, 2025
Unknown status
Keywords
ClinConnect Summary
The study is a prospective randomised clinical phase III trial. The trial will be carried out at Heidelberger Ionenstrahl-Therapie (HIT) centre as monocentric trial.
Proton therapy is the gold standard in the treatment of low and intermediate grad chondrosarcomas of the skull base. However, high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors. Up until now it was impossible to compare two different particle therapies, i.e. proton and carbon ion therapy directly with each other. The aim of this study is to find ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Karnofsky Performance Score ≥60%
- • Age \>18 years and \<80 years
- • Informed consent signed by the patient
- • Histological confirmation of low/ intermediate grade chondrosarcoma with infiltration of the skull base.
- Exclusion Criteria:
- • Inability to understand the aims of the study, no informed consent
- • Prior RT of skull base region
- • Other malignancies with disease-free interval \< 5 years (excepting pre-cancerous lesions)
- • Participation in another trial
- • Pregnancy
- • Simultaneous CHT or Immunotherapy.
About Heidelberg University
Heidelberg University, a prestigious institution located in Germany, is renowned for its commitment to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university fosters a dynamic environment for conducting clinical trials that aim to enhance patient care and improve health outcomes. Leveraging cutting-edge technology and a robust network of healthcare professionals, Heidelberg University is dedicated to exploring novel therapeutic approaches and contributing to the global medical community through rigorous scientific inquiry and ethical research practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, Im Neuenheimer Feld 400, Germany
Patients applied
Trial Officials
Juergen Debus, MD PhD
Principal Investigator
Heidelberg University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials